CORRECTION article

Front. Immunol., 16 July 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1654196

Corrigendum: Case Report: Regenerative hepatic pseudotumor induced by tislelizumab in a lung cancer patient

  • 1Digestive Diseases Center, Department of Hepatopancreatobiliary Medicine, The Second Hospital, Jilin University, Changchun, China
  • 2Department of Respiratory and Critical Care Medicine, The Second Hospital of Jilin University, Changchun, Jilin, China
  • 3Department of Radiology, The Second Hospital of Jilin University, Changchun, China

A Correction on
Case Report: Regenerative hepatic pseudotumor induced by tislelizumab in a lung cancer patient

By Wang W, Li W, Zhang T, Jin Z and Yang L (2025). Front. Immunol. 16:1565065. doi: 10.3389/fimmu.2025.1565065

In the published article, there was an error in the Funding statement. The funder “Natural Science Foundation of Jilin Province (YDZJ202501ZYTS814 and YDZJ202401255ZYTS) to Wenrui Wang” was erroneously omitted.

The correct Funding statement appears below.

“The author(s) declare that financial support was received for the research and/or publication of this article. Natural Science Foundation of Jilin Province (YDZJ202501ZYTS814 and YDZJ202401255ZYT) provided funding to author Wenrui Wang.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: immune checkpoint inhibitors, immune-related adverse events, non-small cell lung cancer, regenerative hepatic pseudotumor, tislelizumab, hepatic immune toxicity, PD-1 inhibitors, immunotherapy complications

Citation: Wang W, Li W, Zhang T, Jin Z and Yang L (2025) Corrigendum: Case Report: Regenerative hepatic pseudotumor induced by tislelizumab in a lung cancer patient. Front. Immunol. 16:1654196. doi: 10.3389/fimmu.2025.1654196

Received: 26 June 2025; Accepted: 07 July 2025;
Published: 16 July 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Wang, Li, Zhang, Jin and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Lanlan Yang, eWxsQGpsdS5lZHUuY29t

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.